Abstract: Nowadays cardiovascular pathology occupies one of the most common positions in special mortality in the world. High residual reactivity of platelet (HRRT) is a predictor of the development of atherothrombosis in patients with coronary heart disease. And also, based on a large number of studies, an associated relationship was found between age, chronic kidney disease (CKD), CYP2C19 genetic polymorphism and HRRT, which leads to the development of atherothrombotic events in patients with coronary heart disease (CHD). Purpose of the study: To analyze sources of literature on issues related to high residual reactivity of platelets, as well as to identify the effect of high residual reactivity of platelets (HRRT) on the development of ischemic events in patients with coronary artery disease and the presence of a correlation between HRRT and various factors, such as age, chronic renal failure. and genetic polymorphism CYP2C19. Search strategy. The search for sources was carried out in such databases as PubMed, Scopus, Web of Science, Medline, Cochrane Library. The search depth was 15 years from 2008 to 2022. 14 literature sources contain important conceptual information on this topic. Inclusion criteria: literature reviews, original articles; publications in open access and with full text in English and Russian languages. Exclusion criteria: publications of low methodological quality, conference proceedings. In total, the literature review included 60 full-text articles, which were critically evaluated. Literature selection algorithm → Studying manuals, monographs on the topic of high residual reactivity of platelets in patients with coronary heart disease → Studying articles from journals, scientific collections, dissertations → Systematization and analysis of material on this topic → Writing an article. Results and conclusions: HERT is a risk factor and predictor of atherothrombosis in patients with acute coronary syndrome or coronary artery disease after stenting, receiving acetylsalicylic acid and clopidogrel, and is also an indicator for modifying antiplatelet therapy to a more effective one to improve the prognosis of patients with coronary artery disease.
Sholpan B. Zhangelova¹, https://orcid.org/0000-0003-3702-5642 Friba N. Nurmukhammad², https://orcid.org/0000-0002-6312-4479 Nursultan Nurdinov², https://orcid.org/0000-0001-5341-7211 ¹ Asfendiarov Kazakh National Medical University, Almaty c., Republic of Kazakhstan; ² International Kazakh-Turkish University named after H.A. Yasaui, Turkestan c., Republic of Kazakhstan.
1. Жангелова Ш.Б., Куанышбекова Р.Т., Капсултанова Д.А., Сафарова И.М., Нурмухаммат Ф.Н., Умирбекова Л.Ж. К оценке эффективности антиагрегантнои терапии у пациентов с ишемическои болезнью сердца // Вестник КазНМУ. 2020. №4. С.114-118. 2. Комаров А.Л., Панченко Е.П. Тестирование функции тромбоцитов для оценки риска тромбозов и кровотечений у больных ибс, получающих антиагреганты // Российский кардиологический журнал 2015. 3 (119): 25–34. http://dx.doi.org/10.15829/1560-4071-2015-03-25-34 (Дата обращения: 10.07.2023) 3. Роль тестирования функциональной активности тромбоцитов в профилактике сердечно-сосудистых осложнений у больных, получающих антитромбоцитарную терапию / Заключение междисциплинарного Совета Экспертов Российского общества ангиологов и сосудистых хирургов, Российского научного общества специалистов по рентгенэндоваскулярной диагностике и лечению, Национальной ассоциации по борьбе с инсультами, Национального научного общества воспаления // Рациональная фармакотерапия в кардиологии 2014. 10(6):679-687 4. Ang L., Thani K.B., Ilapakurti M., Lee M.S., Palakodeti V., Mahmud E. Elevated plasma fibrinogen rather than residual platelet reactivity after clopidogrel pre-treatment is associated with an increased ischemic risk during elective percutaneous coronary intervention // J Am Coll Cardiol. 2013 Jan 8;61(1):23-34. doi: 10.1016/j.jacc.2012.09.037. PMID: 23287370. 5. Angiolillo D.J., Bernardo E., Capodanno D. et al. Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy // J Am Coll Cardiol. 2010. 55(11):1139-1146. 6. Anand SS, Caron F, Eikelboom JW, Bosch J, Dyal L, Aboyans V, Abola MT, Branch KRH, Keltai K, Bhatt DL, Verhamme P, Fox KAA, Cook-Bruns N, Lanius V, Connolly SJ, Yusuf S. Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial // J Am Coll Cardiol. 2018 May 22;71(20):2306-2315. doi: 10.1016/j.jacc.2018.03.008. Epub 2018 Mar 11. PMID: 29540326. 7. Breet N.J., van Werkum J.W., Bouman H.J., Kelder J.C., Ruven H.J., Bal E.T., Deneer V.H., Harmsze A.M., van der Heyden J.A., Rensing B.J., Suttorp M.J., Hackeng C.M., ten Berg J.M. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation // JAMA 2010; 303: 754–62. 8. Cha J.K., Park H.S., Nah H.W., Kim D.H., Kang M.J., Choi J.H., Huh J.T., Suh H.K. High residual platelet reactivity (HRPR) for adenosine diphosphate (ADP) stimuli is a determinant factor for long-term outcomes in acute ischemic stroke with anti-platelet agents: The meaning of HRPR after ADP might be more prominent in large atherosclerotic infarction than other subtypes of AIS // J Thromb Thrombolysis. 2016 Jul. 42(1):107-17. doi: 10.1007/s11239-015-1304-5. PMID: 26680778. 9. Damman P., Varenhorst C., Koul S. et al. Treatment Patterns and Outcomes in Patients Undergoing Percutaneous Coronary Intervention Treated With Prasugrel or Clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]) // Am J Cardiol, 2014, 113: 64e69. 10. De Luca G., Suryapranata H., Marino P. Reperfusion strategies in acute ST-elevation myocardial infarction: an overview of current status // Prog Cardiovasc Dis 2008. 50: 352–82. 11. De Luca G., Verdoia M., Schaffer A., Suryapranata H., Parodi G., Antoniucci D., Marino P. Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience // J Thromb Thrombolysis 2014; 38: 388–94. 12. Di Lorenzo E., Sauro R., Varricchio A., Capasso M., Lanzillo T., Manganelli F., Carbone G., Lanni F., Pagliuca M.R., Stanco G., Rosato G., Suryapranata H., De Luca G. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial // JACC Cardiovasc Interv. 2014. 7: 849–56. 13. Dracoulakis M.D.A., Gurbel P., Cattaneo M., Martins H.S., Nicolau J.C., Kalil Filho R. High Residual Platelet Reactivity during Aspirin Therapy in Patients with Non-St Segment Elevation Acute Coronary Syndrome: Comparison Between Initial and Late Phases // Arq Bras Cardiol. 2019 Aug 15;113(3):357-363. doi: 10.5935/abc.20190146. PMID: 31432979; PMCID: PMC6882399. 14. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Supplementary material. http://eurheartj.oxfordjournals.org/content/ehj/suppl/2013/08/23/eht375.DC1/eht375supp.pdf. 15. Gremmel T., Kopp C.W., Eichelberger B., Koppensteiner R., Panzer S. Sex differences of leukocyte-platelet interactions and on-treatment platelet reactivity in patients with atherosclerosis // Atherosclerosis. 2014 Dec. 237(2):692-5. doi: 10.1016/j.atherosclerosis.2014.10.095. Epub 2014 Oct 29. PMID: 25463107. 16. Gremmel T., Steiner S., Seidinger D., Koppensteiner R., Panzer S., Kopp C.W. Adenosine diphosphate-inducible platelet reactivity shows a pronounced age dependency in the initial phase of antiplatelet therapy with clopidogrel // J Thromb Haemost 2010; 8: 37–42. 17. Guo L.Z., Kim M.H., Jin C.D., Lee J.Y., Yi S.J., Park M.K., Cho Y.R., Park T.H. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects // Platelets. 2014. 2: 1–7. 18. Guo Y., Zhao J., Zhang Y., Wu L., Yu Z., He D., Huang H., Qu W., Luo X. Triglyceride glucose index influences platelet reactivity in acute ischemic stroke patients // BMC Neurol. 2021 Oct 26;21(1):409. doi: 10.1186/s12883-021-02443-x. PMID: 34702218; PMCID: PMC8549262. 19. Joo H.J., Ahn S.G., Park J.H. et al. Effects of genetic variants on platelet reactivity and one-year clinical outcomes after percutaneous coronary intervention: a prospective multicentre registry study // Sci Rep. 2018;8(1):1229. 20. Kamran H., Jneid H., Kayani W.T., Virani S.S., Levine G.N., Nambi V., Khalid U. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review // JAMA. 2021 Apr 20;325(15):1545-1555. doi: 10.1001/jama.2021.0716. Erratum in: JAMA. 2021 Jul 13;326(2):190. PMID: 33877270. 21. Kim Y.G., Suh J.W., Yoon C.H., Oh I.Y., Cho Y.S., Youn T.J., Chae I.H., Choi D.J. Platelet volume indices are associated with high residual platelet reactivity after antiplatelet therapy in patients undergoing percutaneous coronary intervention // J Atheroscler Thromb. 2014;21(5):445-53. doi: 10.5551/jat.20156. Epub 2014 Jan 15. PMID: 24430786. 22. Konishi A., Shinke T., Otake H., Takaya T., Osue T., Kinutani H., Kuroda M., Takahashi H., Terashita D., Hirata K. Impact of residual platelet reactivity under clopidogrel treatment for lesions and the clinical outcome after drug-eluting stent implantation in patients with hemodialysis // J Cardiol. 2016 Jun;67(6):531-7. doi: 10.1016/j.jjcc.2015.07.014. Epub 2015 Aug 20. PMID: 26299610. 23. Knuuti J. et al. ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes // Eur Heart J. 2020 Jan 14. 41(3):407-477. doi: 10.1093/eurheartj/ehz425. PMID: 31504439. 24. Lee S., Wadowski P.P., Hoberstorfer T., Weikert C., Pultar J., Kopp C.W., Panzer S., Gremmel T. Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia // Cardiovasc Drugs Ther. 2021 Feb. 35(1):51-60. doi: 10.1007/s10557-020-07058-x. Epub 2020 Aug 26. PMID: 32845391; PMCID: PMC7808981. 25. Leoncini M., Toso A., Maioli M., Angiolillo D.J., Giusti B., Marcucci R., Abbate R., Bellandi F. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study // JACC Cardiovasc Interv. 2013 Feb;6(2):169-79. doi: 10.1016/j.jcin.2012.09.013. PMID: 23428009. 26. Li J., Pan Y., Xu J., Li S., Wang M., Quan K., Meng X., Li H., Lin J., Wang Y., Zhao X., Liu L., Wang Y. CNSR-III Investigators. Residual Inflammatory Risk Predicts Poor Prognosis in Acute Ischemic Stroke or Transient Ischemic Attack Patients // Stroke. 2021 Aug;52(9):2827-2836. doi: 10.1161/STROKEAHA.120.033152. Epub 2021 Jul 20. PMID: 34281380. 27. Li Q., Chen Y., Liu Y., Yu L., Zheng J., Sun Y. Impact of renal function on residual platelet reactivity and clinical outcomes in patients with acute coronary syndrome treated with clopidogrel // Clin Cardiol. 2021 Jun;44(6):789-796. doi: 10.1002/clc.23588. Epub 2021 May 12. PMID: 33978269; PMCID: PMC8207985. 28. Mencarini T., Roka-Moiia Y., Bozzi S., Redaelli A., Slepian M.J. Electrical impedance vs. light transmission aggregometry: Testing platelet reactivity to antiplatelet drugs using the MICELI POC impedance aggregometer as compared to a commercial predecessor // Thromb Res. 2021 Aug. 204:66-75. doi: 10.1016/j.thromres.2021.05.021. Epub 2021 Jun 5. PMID: 34147831. 29. Muller C, Caillard S., Jesel L. et al. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel // Am J Kidney Dis. 2012;59(6):777-785. 30. Nie X.Y., Li J.L., Zhang Y., Xu Y., Yang X.L., Fu Y., Liang G.K., Lu Y., Liu J., Shi L.W. Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity // J Zhejiang Univ Sci B. 2017 Jan.;18(1):37-47. doi: 10.1631/jzus.B1600333. PMID: 28070995; PMCID: PMC5260476. 31. Parodi G., Bellandi B., Comito V., Capodanno D., Valenti R., Marcucci R., Carrabba N., Migliorini A., Gensini G.F., Abbate R., Antoniucci D. Residual platelet reactivity and outcomes with 5 mg prasugrel therapy in elderly patients undergoing percutaneous coronary intervention // Int J Cardiol 2014; 176: 874–7. 32. Parodi G., Marcucci R., Valenti R., Gori A.M., Migliorini A., Giusti B., Buonamici P., Gensini G.F., Abbate R., Antoniucci D. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI // JAMA. 2011 Sep 21;306(11):1215-23. doi: 10.1001/jama.2011.1332. PMID: 21934054. 33. Pedersen O.B., Pasalic L., Grove E.L., Kristensen S.D., Hvas A.M., Nissen P.H. Advanced Flow Cytometry Using the SYTO-13 Dye for the Assessment of Platelet Reactivity and Maturity in Whole Blood // Methods Protoc. 2023 Jan 13;6(1):8. doi: 10.3390/mps6010008. PMID: 36648957. 34. Pettersen A.A., Arnesen H., Seljeflot I. A brief review on high on-aspirin residual platelet reactivity // Vascul Pharmacol. 2015 Apr-Jun;67-69:6-9. doi: 10.1016/j.vph.2015.03.018. Epub 2015 Apr 11. PMID: 25869498. 35. Pettersen A.А., Seljeflot I., Abdelnoor M., Arnesen H. High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial) // J Am Heart Assoc. 2012 Jun;1(3):e000703. doi: 10.1161/JAHA.112.000703. Epub 2012 Jun 22. PMID: 23130135; PMCID: PMC3487336. 36. Poh X.Y., Loh F.K., Friedland J.S., Ong C.W.M. Neutrophil-Mediated Immunopathology and Matrix Metalloproteinases in Central Nervous System – Tuberculosis // Front Immunol. 2022 Jan 12;12:788976. doi: 10.3389/fimmu.2021.788976. PMID: 35095865; PMCID: PMC8789671. 37. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., Ernst A., Sawhney N.S., Schatz R.A., Teirstein P.S. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation // Eur Heart J. 2008 Apr;29(8):992-1000. doi: 10.1093/eurheartj/ehn046. Epub 2008 Feb 10. PMID: 18263931. 38. Price M.J., Nayak K.R., Barker C.M., Kandzari D.E., Teirstein P.S. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention // Am J Cardiol 2009; 103: 1339–43. 39. Puchinyan N.F., Furman N.V., Dolotovskaya P.V., Malinova L.I. High residual platelet reactivity during dual antiplatelet therapy, found by optical aggregometry and the rate of atherothrombotic complications after coronary artery stenting in patients with ischemic heart disease in clinical practice. Rational Pharmacotherapy in Cardiology, 2016. 12(4). https://doi.org/10.20996/1819-6446-2016-12-4-385-390 (Дата обращения: 10.04.2023) 40. Qureshi A.I., Jahngir M.U., Qualls K., Akinci Y., Lobanova I., Liaqat J., Gao X., Akhtar I.N., Kraus J., Uzun G., French B., Siddiq F., Ramiro Gomez C. The Effect of Ticagrelor on Platelet Reactivity in Patients with Clopidogrel Resistance Undergoing Neuroendovascular Procedures // J Neuroimaging. 2020 May;30(3):327-334. doi: 10.1111/jon.12714. Epub 2020 Apr 17. PMID: 32301181. 41. Rosińska J., Maciejewska J., Narożny R., Kozubski W., Łukasik M. Association of platelet-derived microvesicles with high on-treatment platelet reactivity in convalescent ischemic stroke patients treated with acetylsalicylic acid // Wiad Lek. 2019 Aug 31.72(8):1426-1436. PMID: 31999906. 42. Roule V., Heudel T., Lemaitre A., Bignon M., Ardouin P., Sabatier R., Blanchart K., Beygui F. Residual platelet reactivity after pre-treatment with ticagrelor prior to primary percutaneous coronary intervention is associated with suboptimal myocardial reperfusion // Eur Heart J Acute Cardiovasc Care. 2019 Aug 12:2048872619860214. doi: 10.1177/2048872619860214. Epub ahead of print. PMID: 33609114. 43. Samos M., Fedor M., Kovar F., Mokan M., Bolek T., Galajda P., Kubisz P., Mokan M. Type 2 Diabetes and ADP Receptor Blocker Therapy // J Diabetes Res. 2016;2016:6760710. doi: 10.1155/2016/6760710. Epub 2015 Dec 28. PMID: 26824047; PMCID: PMC4707344. 44. Schrick D., Molnar T, Tokes-Fuzesi M., Molnar A., Ezer E. Circulating Microvesicles in Convalescent Ischemic Stroke Patients: A Contributor to High-On-Treatment Residual Platelet Reactivity? // Front Biosci (Landmark Ed). 2022 May 16;27(5):158. doi: 10.31083/j.fbl2705158. PMID: 35638425. 45. Sibbing D., Braun S., Morath T., Mehilli J., Vogt W., Schomig A., Kastrati A., von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drugeluting stent thrombosis // J Am Coll Cardiol. 2009. 53: 849–56. 46. Siller-Matula J.M., Gruber C., Francesconi M., Dechant C., Jilma B., Delle-Karth G., Grohs K., Podczeck-Schweighofer A., Christ G. The net clinical benefit of personalized antiplatelet therapy in patients undergoing percutaneous coronary intervention // Clin Sci (Lond) 2015; 128: 121–30. 47. Silvain J., Cayla G., Hulot J.S., Finzi J., Kerneis M., O’Connor S.A., Bellemain-Appaix A., Barthelemy O., Beygui F., Collet J.P., Montalescot G. High on-thienopyridine platelet reactivity in elderly coronary patients: the senior-platelet study // Eur Heart J 2012; 33: 1241–9. 48. Tang N., Yin S., Sun Z., Xu X., Qin J. The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients // Scand J Clin Lab Invest. 2015 May. 75(3):223-9. doi: 10.3109/00365513.2014.993696. Epub 2015 Jan 16. PMID: 25594796. 49. Tantry U.S., Bonello L., Aradi D. For the Working Group on On-Treatment Platelet Reactivity. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated With Ischemia and Bleeding // J Am Coll Cardiol 2013; 62: 2261-73. 50. Tesfamariam B. Impact of Reticulated Platelets on Platelet Reactivity in Neonates // J Cardiovasc Pharmacol Ther. 2021 Nov;26(6):585-592. doi: 10.1177/10742484211041238. Epub 2021 Aug 23. PMID: 34420426. 51. Valenti R, Marcucci R., Capodanno D., De Luca G., Migliorini A., Gori A.M., et al. Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) study // J Thromb Thrombolysis. 2015 Jul;40(1):76-82. doi: 10.1007/s11239-014-1159-1. PMID: 25502874. 52. Verdoia M., Pergolini P., Rolla R., Nardin M., Barbieri L., Schaffer A. et al. Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor // Expert Opin Pharmacother. 2015. 16: 1739–47. 53. Venetsanos D., Sederholm Lawesson S., Swahn E., Alfredsson J. Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: The inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial // Thromb Res. 2017 Jan;149:88-94. doi: 10.1016/j.thromres.2016.10.013. Epub 2016 Oct 15. PMID: 27773347. 54. Verdoia M., Pergolini P., Rolla R., Nardin M., Barbieri L., Schaffer A., Bellomo G., Marino P., Suryapranata H., De Luca G. Novara Atherosclerosis Study Group (NAS). Platelet Larger Cell Ratio and High-on Treatment Platelet Reactivity During Dual Antiplatelet Therapy // Cardiovasc Drugs Ther. 2015;29(5):443-50. doi: 10.1007/s10557-015-6616-3. PMID: 26428927. 55. Verdoia M., Pergolini P., Rolla R. et al. Novara Atherosclerosis Study Group (NAS). Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor // Cardiovasc Ther. 2016 Aug;34(4):209-15. doi: 10.1111/1755-5922.12188. PMID: 27086085. 56. Verdoia M., Pergolini P., Rolla R. et al. Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor // J Thromb Haemost. 2016 Jan;14(1):57-64. doi: 10.1111/jth.13177. Epub 2015 Dec 29. PMID: 26512550 57. Gori A.M., Cesari F., Marcucci R., Giusti B., Paniccia R., Antonucci E., Gensini G.F., Abbate R. The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients // Atherosclerosis. 2009 Jan;202(1):255-62. doi: 10.1016/j.atherosclerosis.2008.04.001. Epub 2008 Apr 11. PMID: 18486134. 58. Wang Z., Gao F., Men J., Yang J., Modi P., Wei M. Polymorphisms and high on-aspirin platelet reactivity after off-pump coronary artery bypass grafting // Scand Cardiovasc J. 2013 Aug;47(4):194-9. doi: 10.3109/14017431.2013.800640. Epub 2013 May 31. PMID: 23688183. 59. Warlo E.M.K., Pettersen A.R., Arnesen H., Seljeflot I. vWF/ADAMTS13 is associated with on-aspirin residual platelet reactivity and clinical outcome in patients with stable coronary artery disease // Thromb J. 2017 Nov 22;15:28. doi: 10.1186/s12959-017-0151-3. PMID: 29200971; PMCID: PMC5700557. 60. Yamamoto K., Hokimoto S., Chitose T., Morita K., Ono T., Kaikita K., Tsujita K., Abe T., Deguchi M., Miyagawa H., Saruwatari J., Sumida H., Sugiyama S., Nakagawa K., Ogawa H. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy // J Cardiol. 2011 Mar;57(2):194-201. doi: 10.1016/j.jjcc.2010.10.007. Epub 2010 Dec 17. PMID: 21168310. References: 1. Zangelova Sh.B., Kuanyshbekova R.T., Kapsultanova D.A., Safarova I.M., Nurmuhammat F.N., Umirbekova L.J. K otsenke effectivnosti antiagregantnoi terapii u patsientov s ishemicheskoi bolesniyu serdtsa [Evaluation of antiplatelet therapy in patients with ischemic heart disease]. Vestnik KazNMU [Bulletin of the Kaznmu] 2020. №4. pp.114-118. [in Russian]. 2. Komarov A.L., Panchenko E.P. Testirovanie functsii trombotsitov dlya otsenki riska trombosov i krovotechenii u bolnykh IBS, poluchaushikh antiagreganty. [Testing of platelet fuction for assessment of the risk of thrombosis and bleeding in patients with coronary artery disease receiving antiplatelet agents]. Rossiiskii kardiologicheskii zhurnal [Russian Journal of Cardiology]. 2015. 3(119), 25-34. [in Russian]. 3. Rol testirovaniya funktsionalnoi aktivnosti trombotsitov v profilaktike serdechno-sosudistykh oslozhnenii u bolnykh, poluchaushikh antitrombotsitarnuyu terapiyu [The role of testing the functional activity of platelets in the prevention of cardiovascular complications in patients receiving antiplatelet therapy] / Zaklyuchenie mezhdistsiplenarnogo Soveta Ekspertov Rossiiskogo obshestva angiologov i sosudistykh khirurgov, Rossiiskogo nauchnogo obshestva spetsialistov po roentgen endovaskuliyarnoi diagnostike I lecheniyu. Natsionalnoi assotsiatsii po borbe s insultami, Natsionalnogo nauchnogo obshestva vospaleniya [Conclusion of the interdisciplinary Council of Experts of the Russian Society of Angiologists and Vascular Surgeons, the Russian Scientific Society of Specialists in X-ray Endovascular Diagnosis and Treatment, the National Association for Stroke Control, the National Scientific Society of Inflammation]. Ratsionalnaya farmakoterapiya v kardiologii [Rational pharmacotherapy in cardiology]. 2014. 10(6):679-687[in Russian].
Number of Views: 23

Key words:

Bibliography link

Zhangelova Sh.B., Nurmukhammad F.N., Nurdinov N. High residual reactivity of platelets as a predictor of atherothrombosis in patients with coronary heart disease // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 3, pp. 185-195. DOI 10.34689/SH.2023.25.3.025

Авторизируйтесь для отправки комментариев